Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use BEIZRAY safely and effectively. See full prescribing information for BEIZRAY.BEIZRAY (docetaxel) injection, for intravenous useInitial U.S. Approval: 1996
Medication labelWhy this: Advisory · dailymed-prescription
BEIZRAY is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. BEIZRAY in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. BEIZRAY as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. BEIZRAY in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. BEIZRAY in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. BEIZRAY in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. BEIZRAY in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
- generic_name
- docetaxel
- brand_name
- Albumin human
- product_names
- docetaxel, Docetaxel, Albumin human
- ndc
- 70710-2090, 70710-2091, 70710-2092, 70710-2093, 70710-2152, 64208-2512, 70710-2091-3, 70710-2090-1, 64208-2512-4, 70710-2093-4, 70710-2152-1, 70710-2092-8
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en